VIPoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(10 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{VIPoma}}
{{VIPoma}}
{{CMG}}{{AE}}{{PSD}}
{{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}}
==Overview==
==Overview==
If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref>Common complications of VIPoma include [[Metastasis]] [[Cardiac arrest]] from low blood [[potassium]] level, and [[Dehydration]]. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma. VIPoma is associated with a 5 year survival rate of 20% and 3 year survival rate of 40%.<ref name="SmithBranton1998">{{cite journal|last1=Smith|first1=Stephen L.|last2=Branton|first2=Susan A.|last3=Avino|first3=Anthony J.|last4=Martin|first4=J.Kirk|last5=Klingler|first5=Paul J.|last6=Thompson|first6=Geoffrey B.|last7=Grant|first7=Clive S.|last8=van Heerden|first8=Jon A.|title=Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature|journal=Surgery|volume=124|issue=6|year=1998|pages=1050–1055|issn=00396060|doi=10.1067/msy.1998.92005}}</ref>
If left untreated, [[patients]] with VIPoma may progress to [[Development|develop]] [[watery diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]]. Common [[complications]] of VIPoma include [[metastasis]], [[cardiac arrest]] from [[low blood potassium]] level, and [[dehydration]]. The presence of [[metastasis]] is associated with a particularly poor [[prognosis]] among [[patients]] with VIPoma, with a 5 year [[survival rate]] of 60%.


==Natural History==
==Natural History==
*If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref>
*If left untreated, [[patients]] with VIPoma may progress to [[Development|develop]] [[watery diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref>
*VIPoma have a very slow growth rate compared to most malignant tumors.
*VIPoma have a very slow [[growth]] rate compared to the most [[malignant tumors]].


==Complications==
==Complications==
Common complications of VIPoma include:
Common [[complications]] of VIPoma include:<ref>{{Cite journal
| author = [[J. V. VERNER]] & [[A. B. MORRISON]]
| title = Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia
| journal = [[The American journal of medicine]]
| volume = 25
| issue = 3
| pages = 374–380
| year = 1958
| month = September
| doi = 10.1016/0002-9343(58)90075-5
| pmid = 13571250
}}</ref><ref>{{Cite journal
| author = [[A. Ayub]], [[M. Zafar]], [[A. Abdulkareem]], [[M. A. Ali]], [[T. Lingawi]] & [[A. Harbi]]
| title = Primary hepatic vipoma
| journal = [[The American journal of gastroenterology]]
| volume = 88
| issue = 6
| pages = 958–961
| year = 1993
| month = June
| pmid = 8389095
}}</ref>
* [[Metastasis]]
* [[Metastasis]]
* [[Cardiac arrest]] from low blood [[potassium]] level
* [[Cardiac arrest]] from [[low blood potassium]] level
* [[Dehydration]]
* [[Dehydration]]


==Prognosis==
==Prognosis==
*Surgery can usually cure VIPomas. However, in one-third to one-half of patients, the tumor has spread by the time of diagnosis and cannot be cured.
*[[Surgery]] can usually [[cure]] VIPomas. However, in one-third to one-half of [[patients]], the [[tumor]] has [[Spread of the cancer|spread]] by the time of [[diagnosis]] and cannot be [[Cure|cured]].<ref name="pmid27583474">{{cite journal| author=Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E| title=Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 10 | pages= 3564-3567 | pmid=27583474 | doi=10.1210/jc.2016-2051 | pmc=5052354 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27583474  }}</ref>
*VIPoma is associated with a 5 year survival rate of 20% and 3 year survival rate of 40%.<ref name="SmithBranton1998">{{cite journal|last1=Smith|first1=Stephen L.|last2=Branton|first2=Susan A.|last3=Avino|first3=Anthony J.|last4=Martin|first4=J.Kirk|last5=Klingler|first5=Paul J.|last6=Thompson|first6=Geoffrey B.|last7=Grant|first7=Clive S.|last8=van Heerden|first8=Jon A.|title=Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature|journal=Surgery|volume=124|issue=6|year=1998|pages=1050–1055|issn=00396060|doi=10.1067/msy.1998.92005}}</ref>
*The 5-year [[Survival rate|survival]] for [[patients]] with localized VIPoma is 94%  whereas [[metastatic]] [[pancreatic]] VIPomas is 60%, respectively.
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Endocrinology]]
[[Category:Types of cancer]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Endocrinology]]
[[Category:Gastroenterology]]

Latest revision as of 00:40, 30 July 2020

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma natural history, complications and prognosis

CDC on VIPoma natural history, complications and prognosis

VIPoma natural history, complications and prognosis in the news

Blogs on VIPoma natural history, complications and prognosis

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy. Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 60%.

Natural History

Complications

Common complications of VIPoma include:[2][3]

Prognosis

References

  1. Natanzi, Naveed; Amini, Mazyar; Yamini, David; Nielsen, Shawn; Ram, Ramin (2009). "Vasoactive Intestinal Peptide Tumor". Scholarly Research Exchange. 2009: 1–7. doi:10.3814/2009/938325. ISSN 1687-8299.
  2. J. V. VERNER & A. B. MORRISON (1958). "Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia". The American journal of medicine. 25 (3): 374–380. doi:10.1016/0002-9343(58)90075-5. PMID 13571250. Unknown parameter |month= ignored (help)
  3. A. Ayub, M. Zafar, A. Abdulkareem, M. A. Ali, T. Lingawi & A. Harbi (1993). "Primary hepatic vipoma". The American journal of gastroenterology. 88 (6): 958–961. PMID 8389095. Unknown parameter |month= ignored (help)
  4. Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E (2016). "Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report". J Clin Endocrinol Metab. 101 (10): 3564–3567. doi:10.1210/jc.2016-2051. PMC 5052354. PMID 27583474.


Template:WikiDoc Sources